-+ 0.00%
-+ 0.00%
-+ 0.00%

Sandoz Publishes Nine-Month 2026 Sales Update Presentation

PUBT·10/28/2026 06:05:29
Sandoz Publishes Nine-Month 2026 Sales Update Presentation
  • Sandoz reported a 40-asset biosimilar pipeline in its nine-month 2026 sales update.
  • Biosimilar pertuzumab reached regulatory submission in the European Union.
  • Pyzchiva held the leading biosimilar position across major European markets; global biosimilar penetration reached 54%.
  • Hyrimoz continued gaining European market share, supported by strong volume momentum.
  • Afqlir launched across 22 European markets, becoming a key contributor to regional growth.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.